Form 4: Exact Sciences EVP Sells $375K in Stock Under 10b5-1 Plan
Insider Transaction Report
Exact Sciences EVP, Jacob A. Orville, sold 5,000 shares of common stock for $75 per share, totaling $375,000, under a pre-arranged 10b5-1 plan.
Summary
- Jacob A. Orville, Executive Vice President and General Manager of Screening at Exact Sciences Corp. (EXAS), reported a sale of common stock.
- The transaction involved the disposition of 5,000 shares of common stock on November 19, 2025.
- Each share was sold at a price of $75, resulting in a total transaction value of $375,000.
- The sale was executed pursuant to a Rule 10b5-1 trading plan, which was established on May 27, 2025.
- Following this transaction, Mr. Orville directly beneficially owns 23,237 shares of common stock.
- Additionally, Mr. Orville indirectly holds 1,490 shares of common stock in a 401(k) Plan.
- Mr. Orville also holds an aggregate of 79,661 vested and unvested options to purchase common stock and restricted stock units.
Sentiment
Score: 5
Explanation: The filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan, which is generally considered a neutral event not reflecting a change in company fundamentals or management's outlook.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This is a routine insider transaction and does not provide specific insights into broader industry trends or competitive landscape. Such sales are common for executives managing personal finances or diversifying portfolios.
Stakeholder Impact
- Shareholders: Minimal impact as this is a pre-planned, routine insider sale and does not typically signal a change in company fundamentals or management confidence.
Key Dates
| Date | Description |
|---|---|
| 05/27/2025 | Date Rule 10b5-1 trading plan was entered into. |
| 11/19/2025 | Date of common stock transaction (sale). |
| 11/21/2025 | Date of Form 4 filing. |
Recommendation
holdThe filing reports a routine insider stock sale executed under a pre-arranged 10b5-1 trading plan. This type of transaction is generally not indicative of a change in management's outlook on the company's fundamentals and does not provide new information to warrant a change in investment recommendation. Investors should continue to evaluate the company based on its financial performance and strategic initiatives.
Keywords
EXAS, Exact Sciences, insider trading, Form 4, stock sale, 10b5-1 plan, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.